BioAegis Therapeutics Announces Appointment of Two New Corporate Board Members
17 févr. 2022 17h42 HE
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases...
Protocol Design Optimization Is Starting to Improve Clinical Study Performance, According to the Tufts Center for the Study of Drug Development
09 sept. 2014 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Sep 9, 2014) - Efforts by drug companies to streamline and improve the execution of clinical study designs -- to counter mounting costs and shorten development times...
Drug Company Collaborations to Reduce Development Risk Are Increasing, According to Tufts Center for the Study of Drug Development
07 août 2014 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Aug 7, 2014) - As pharmaceutical and biotech companies look to speed development, lower cost, and reduce technical risks associated with new drug development, they are...
Orphan Drug Approvals Have Increased, But High Costs Pose Challenges for Patients, According to the Tufts Center for the Study of Drug Development
10 juil. 2014 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jul 10, 2014) - Although the pace of approvals for new orphan drugs -- medicines that treat relatively rare conditions -- have increased in the United States and Europe...
Risk-Sharing Drug Development Programs Experience Longer Development Times, According to the Tufts Center for the Study of Drug Development
08 mai 2014 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - May 8, 2014) - Drug development programs that involve several partners who share clinical development risks accounted for about half of all new therapeutic drug approvals...
Drug Developers Circumspect About Using Social Media in Clinical Research, According to the Tufts Center for the Study of Drug Development
06 mars 2014 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Mar 6, 2014) - Social media is gaining ground as an important tool to improve the clinical research process through more effective engagement of patient communities, but...
New Breakthrough Therapy Designation Has Potential to Shorten Development Time Considerably, According to the Tufts Center for the Study of Drug Development
23 janv. 2014 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 23, 2014) - The recently launched Breakthrough Therapy Designation (BTD) program in the United States, aimed at expediting development and review of drugs intended to...
Drug Developers Are Implementing New Strategies for Use of Comparator Drugs in Clinical Trials, According to Tufts Center for the Study of Drug Development
16 janv. 2014 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 16, 2014) - Drug developers are aggressively implementing new strategies to improve their access to and use of comparator drugs, which are used in clinical trials to...
Drug Company Success Depends on New Development Paradigms, According to Tufts Center for the Study of Drug Development
07 janv. 2014 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 7, 2014) - While many drug developers continue to improve clinical trial operational efficiency to increase the pace of new product introductions, their medium- and...
Biotech Products in Big Pharma Clinical Pipelines Have Grown Dramatically According to the Tufts Center for the Study of Drug Development
14 nov. 2013 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Nov 14, 2013) - The pharmaceutical industry, especially Big Pharma, has dramatically shifted its R&D focus from its historical concentration on small molecule drugs...